Shares of Merck & Co. (MRK) declined sharply during Monday's trading session, closing down 3.9% at $117.16. The drop significantly underperformed the broader equity indices, which managed to eke out modest gains. The sell-off reflects growing investor apprehension surrounding the pharmaceutical giant's long-term earnings trajectory and mounting patent expiration headwinds.
The downward pressure was not isolated to Merck. The healthcare sector broadly lagged the market, with fellow Dow Jones Industrial Average component Amgen (AMGN) falling approximately 2.2%. Other major drugmakers, including Pfizer (PFE) and AbbVie (ABBV), also traded lower, each shedding nearly 1%. The collective weakness in these heavyweight stocks contributed to the Dow Jones index underperforming its peers on the day.
The primary catalyst for Merck's decline stems from financial guidance provided just last week. The company outlined its 2026 sales target, projecting revenue in a range of $65.5 billion to $67.0 billion. Concurrently, it issued non-GAAP earnings per share (EPS) guidance between $5.00 and $5.15. While the fourth-quarter 2025 results showed a 5% year-over-year sales increase to $16.4 billion, driven by a 7% jump in Keytruda revenue to $8.37 billion, the future outlook has given investors pause.
Central to the concern is a projected $2.5 billion financial hit anticipated in 2026. Management attributed this to a combination of factors: intensified generic competition for older drugs, the impact of Medicare drug price negotiations, and notably weaker sales of its COVID-19 antiviral treatment, Lagevrio. CEO Rob Davis highlighted a "disconnect" between the company's internal forecasts and more optimistic analyst models, explicitly pointing to patent expirations as the core issue. Analyst commentary, such as from BMO Capital's Evan Seigerman, noted the results provided a "reasonable foundation" but cautioned that the revenue outlook may temper expectations.
Beyond the headline numbers, Merck's product portfolio showed mixed performance. While the oncology blockbuster Keytruda remains a powerhouse, the Gardasil vaccine franchise saw a steep 34% decline in sales to $1.03 billion, which the company linked to reduced demand in China. On the regulatory front, Merck provided an update on WINREVAIR, noting the U.S. Food and Drug Administration (FDA) has set a target action date of September 21, 2026, for a label update submission.
In a bid to diversify its growth engines, Merck is investing in new therapeutic areas. On Monday, its Canadian division announced that Health Canada approved ENFLONSIA (clesrovimab), a monoclonal antibody, for the prevention of RSV lower respiratory tract disease in infants. However, the immediate market reaction suggests traders are currently more focused on the transition away from current blockbusters than on individual pipeline victories.
The overarching narrative for Merck, and the sector at large, is one of a pivotal transition. Investors are grappling with the timing challenge: the pace at which revenue from aging, patent-protected drugs may decelerate versus the speed at which new products can gain commercial traction and offset those losses. With Keytruda's own patent cliff looming further on the horizon, the company's medium-term reliance on its flagship drug remains a key focus for the Street.
Looking ahead, broader macroeconomic data could influence trading in defensive sectors like healthcare. Market participants are awaiting the February 11 jobs report and the February 13 Consumer Price Index (CPI) reading, as detailed on the Bureau of Labor Statistics (BLS) calendar. These releases may shift expectations for Federal Reserve interest rate policy, potentially adding another layer of volatility. Merck is scheduled to report its next quarterly earnings on April 30.
